0000899243-20-001061.txt : 20200113 0000899243-20-001061.hdr.sgml : 20200113 20200113161959 ACCESSION NUMBER: 0000899243-20-001061 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20200101 FILED AS OF DATE: 20200113 DATE AS OF CHANGE: 20200113 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Keutzer Timothy CENTRAL INDEX KEY: 0001798155 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38266 FILM NUMBER: 20523985 MAIL ADDRESS: STREET 1: C/O SPERO THERAPEUTICS, INC. STREET 2: 675 MASSACHUSETTS AVENUE, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Spero Therapeutics, Inc. CENTRAL INDEX KEY: 0001701108 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 675 MASSACHUSETTS AVENUE STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-242-1600 MAIL ADDRESS: STREET 1: 675 MASSACHUSETTS AVENUE STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Spero Therapeutics, LLC DATE OF NAME CHANGE: 20170316 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2020-01-01 0 0001701108 Spero Therapeutics, Inc. SPRO 0001798155 Keutzer Timothy C/O SPERO THERAPEUTICS, INC. 675 MASSACHUSETTS AVENUE, 14TH FLOOR CAMBRIDGE MA 02139 0 1 0 0 Chief Development Officer Common Stock 2500 D Stock Option (Right to Buy) 5.90 2027-07-05 Common Stock 10695 D Stock Option (Right to Buy) 5.90 2027-07-05 Common Stock 7311 D Stock Option (Right to Buy) 5.90 2027-07-05 Common Stock 987 D Stock Option (Right to Buy) 5.90 2027-07-05 Common Stock 36950 D Stock Option (Right to Buy) 11.63 2027-12-12 Common Stock 25016 D Stock Option (Right to Buy) 6.26 2029-01-02 Common Stock 25000 D Reflects shares that were purchased through a directed share program in connection with the Issuer's initial public offering. All shares underlying this option are fully vested. The number of underlying shares of common stock and the exercise price reported reflect a 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017. The shares underlying this option vested as to 25% on April 28, 2017, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. All shares underlying this option are fully vested. The shares underlying this option vested as to 25% on July 6, 2018, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. The shares underlying this option vested as to 25% on December 13, 2018, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. The shares underlying this option vested as to 25% on January 2, 2020, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Exhibit 24.1 - Power of Attorney /s/ Brian J. Shea, Attorney-in-Fact for Timothy Keutzer 2020-01-13 EX-24.1 2 attachment1.htm EX-24.1 DOCUMENT

                               POWER OF ATTORNEY

      Know all by these present, that the undersigned hereby constitutes and
appoints each of Ankit Mahadevia, Chief Executive Officer and President of Spero
Therapeutics, Inc. (the "Company"), Bethany Calagione of the Company, and
Matthew J. Gardella, Matthew W. Tikonoff, Brian J. Shea, Samantha M. Silver,
Anne T. Leland, Brenda L. Meyette and Jacquelyn Cannata of Mintz, Levin, Cohn,
Ferris, Glovsky and Popeo, P.C., signing singly, with full power of
substitution, the undersigned's true and lawful attorney-in-fact to:

      (1)     execute for and on behalf of the undersigned, forms and
              authentication documents for EDGAR Filing Access;

      (2)     do and perform any and all acts for and on behalf of the
              undersigned which may be necessary or desirable to complete and
              execute any such forms and authentication documents;

      (3)     execute for and on behalf of the undersigned, in the undersigned's
              capacity as an officer, director and/or 10% shareholder of the
              Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the
              Securities Exchange Act of 1934 and the rules thereunder;

      (4)     do and perform any and all acts for and on behalf of the
              undersigned which may be necessary or desirable to complete and
              execute any such Form 3, 4 or 5 and timely file such form with the
              United States Securities and Exchange Commission and any stock
              exchange or similar authority; and

      (5)     take any other action of any type whatsoever in connection with
              the foregoing which, in the opinion of such attorney-in-fact, may
              be of benefit to, in the best interests of, or legally required by
              the undersigned, it being understood that the documents executed
              by such attorney-in-fact on behalf of the undersigned pursuant to
              this Power of Attorney shall be in such form and shall contain
              such terms and conditions as such attorney-in-fact may approve in
              such attorney-in-fact's discretion.

      The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934, as amended.

      This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.

      IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed this 23rd day of December, 2019


                                       /s/ Timothy Keutzer
                                      ---------------------------------------
                                               Signature

                                       Timothy Keutzer
                                      ---------------------------------------
                                               Print Name